|Awarded On||February 19, 2020|
|Title||KRAS Spatiotemporal Dynamics: Novel Therapeutic Targets|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Health Science Center at Houston|
|Principal Investigator/Program Director||John F Hancock|
|Cancer Sites||Colorectal, Lung and Bronchus, Pancreas|
RAS is a protein that operates as a molecular switch, toggling between an active “on- state” and an inactive “off-state” in response to growth signals received by the cell. When RAS is in the “on-state” it activates a signaling network that instructs the cell to divide. Unfortunately, 15-20% of all human tumors acquire mutations that lock the RAS switch in the “on-state”. Cells with a mutant RAS switch therefore receive a constant signal to undergo cell division, resulting in the outgrowth of a tumor. The major clinical problem is with a form of RAS called KRAS that is mutated in more than 90% of pancreatic cancers, approximately 50% of colon cancers and 25% of non-small cell lung cancers. W...